W-G Lan1, Y-Z Hao2, D-H Xu1, P Wang3, Y-L Zhou4, L-B Ma1. 1. Department of Oncology, Binzhou Medical University Hospital, Binzhou, China. 2. Department of Oncology, Binzhou Medical University Hospital, Binzhou, China. drhaoyzh@126.com. 3. Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou, China. 4. Department of Pharmacy, Binzhou Medical University Hospital, Binzhou, China.
Abstract
AIM: To investigate the role of human epididymis protein 4 (HE4) in the diagnosis and prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT). METHODS: A total of 218 patients with LA-NSCLC were enrolled. All patients underwent CRT. The treatment response to CRT was evaluated. The prognosis analysis was performed using relapse-free survival (RFS) and overall survival [1]. RESULTS: Our data show that the serum HE4 can discriminate patients who respond well to CRT from those who respond poorly. Higher serum HE4 had dramatically increased risk of being non-responders to CRT. Serum HE4 level is also associated with prognosis of patients after CRT. Patients with high HE4 level had shorter RFS and OS compared to those with low HE4 level. CONCLUSION: Our data suggest that serum HE4 may be a useful prognostic biomarker for LA-NSCLC patients who underwent CRT.
AIM: To investigate the role of humanepididymis protein 4 (HE4) in the diagnosis and prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT). METHODS: A total of 218 patients with LA-NSCLC were enrolled. All patients underwent CRT. The treatment response to CRT was evaluated. The prognosis analysis was performed using relapse-free survival (RFS) and overall survival [1]. RESULTS: Our data show that the serum HE4 can discriminate patients who respond well to CRT from those who respond poorly. Higher serum HE4 had dramatically increased risk of being non-responders to CRT. Serum HE4 level is also associated with prognosis of patients after CRT. Patients with high HE4 level had shorter RFS and OS compared to those with low HE4 level. CONCLUSION: Our data suggest that serum HE4 may be a useful prognostic biomarker for LA-NSCLCpatients who underwent CRT.
Entities:
Keywords:
Concurrent chemoradiotherapy; Human epididymis protein 4; Locally advanced non-small cell lung cancer; Prognosis
Authors: Cetin Ordu; Nalan A Selcuk; Cengiz Akosman; Orhan Onder Eren; Elif C Altunok; Turkay Toklu; Basak Oyan Journal: Asian Pac J Cancer Prev Date: 2015
Authors: Béla Nagy; Harjit Pal Bhattoa; Zoltán Steiber; Mária Csobán; Mária Szilasi; Gábor Méhes; Mónika Müller; József Lázár; János Kappelmayer; Péter Antal-Szalmás Journal: Clin Chem Lab Med Date: 2014-11 Impact factor: 3.694
Authors: Jae Eun Choi; John Villarreal; Javier Lasala; Vijaya Gottumukkala; Reza J Mehran; David Rice; Jun Yu; Lei Feng; Juan P Cata Journal: Cancer Med Date: 2015-03-10 Impact factor: 4.452
Authors: Ho Il Yoon; Oh-Ran Kwon; Kyung Nam Kang; Yong Sung Shin; Ho Sang Shin; Eun Hee Yeon; Keon Young Kwon; Ilseon Hwang; Yoon Kyung Jeon; Yongdai Kim; Chul Woo Kim Journal: J Cancer Prev Date: 2016-09-30